About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, RP-323, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

February 6

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA’s Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia View Release

October 23

Rich Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to FDA for the Treatment of Acute Myelocytic Leukemia and Myelodysplastic Syndrome View Release

October 13

Rich Pharmaceuticals Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights for Indication, Patents and Intellectual Property Related to the Treatment of Hodgkin’s Lymphoma View Release

» Read Latest News